The biotin-conjugated SLC30A8 antibody is primarily used to study β-cell function, diabetes pathogenesis, and zinc homeostasis. Key applications include:
Quantitative detection of SLC30A8 in serum, plasma, or tissue homogenates .
Sensitivity: 0.188-0.313 ng/mL (detection range: 0.313-20 ng/mL) .
Protocol:
SLC30A8 loss-of-function variants reduce type 2 diabetes (T2D) risk by enhancing insulin secretion and β-cell function .
Complete knockout (homozygous) shows stronger protection than heterozygous variants, with a 71% reduced T2D risk .
Zinc transport: SLC30A8 mediates zinc accumulation in insulin granules, critical for hexamer formation and secretion .
Autoantibodies: Anti-SLC30A8 antibodies are linked to type 1 diabetes, indicating its role as an autoantigen .